vimarsana.com

Page 7 - Diffuse Largeb Cell Lymphoma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Unmet Needs in First-Line DLBCL Treatment

Sonali Smith, MD, discusses the current unmet needs in 1L DLBCL treatment.

Sonali smithNew treatment optionsSequencing therapeutic choicesDiffuse largeb cell lymphomaDlbcl treatmentsDlbcl therapiesDlbcl unmet needs

Clinical Challenges: Using Pola-R-CHP for Diffuse Large B-Cell Lymphoma

Regimen is approved for frontline treatment, but when it represents the best choice is less clear

United statesLeah lawrenceJakub svobodaMichael jainMoffitt cancer centerNational comprehensive cancer networkPenn medicineB cell lymphomaDiffuse largeb cell lymphoma

Bispecific Antibodies in DLBCL: Therapeutic Potential

Robert Mancini, PharmD, discusses current DLBCL (diffuse large B cell lymphoma) management approaches, relapse rates, frontline, and subsequent therapies, including emerging treatments like bispecific T-cell engagers and monoclonal antibodies.

Robert manciniEmerging roleBispecific antibodiesDiffuse largeb cell lymphoma managementDiffuse largeb cell lymphomaClinical effectivenessSafety profilesMultidisciplinary careTherapy approachesRelapse ratesEmerging treatmentsBispecifict cell engagers

Odronextamab Exhibits Continued Clinical Activity and Tolerable Safety Profile in R/R DLBCL

Odronextamab produced durable responses and a generally manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.

Sabarish ram ayyappanRegeneron pharmaceuticalsEuropean organization for research of cancerCity of hope cancer treatment centerRam ayyappanHope cancer treatment centerEuropean organizationAnn arborPrescription drug user fee actDiffuse largeb cell lymphomaFollicular lymphomaPrespecified analysisPivotal phasePatients with relapsed refractory diffuse largeb cell lymphomaElm 2 trial

NX-1607 Is Under Phase 1 Evaluation in DLBCL and Other Advanced Malignancies

The phase 1a/1b NX-1607-101 trial will evaluate NX-1607, a CBL-B inhibitor, in patients with advanced malignancies, including diffuse large B-cell lymphoma.

United statesUnited kingdomNx 1607 101 trialNx 1607Patients with advanced malignanciesDiffuse largeb cell lymphoma

vimarsana © 2020. All Rights Reserved.